Litigation Details for BAUSCH HEALTH IRELAND LIMITED v. LUPIN INC. (D.N.J. 2019)

BAUSCH HEALTH IRELAND LIMITED v. LUPIN INC. (D.N.J. 2019)

Docket		Date Filed	2019-04-01
Court	District Court, D. New Jersey	Date Terminated	2021-09-20
Cause	35:271 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	Defendant	Referred To	Karen M. Williams
Parties	LUPIN INC.
Patents	10,016,504; 8,999,313; 9,326,969; 9,592,252; 9,707,297
Link to Docket	External link to docket

Details for BAUSCH HEALTH IRELAND LIMITED v. LUPIN INC. (D.N.J. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-04-01				External link to document
2019-04-01	1		(“the ʼ252 patent”); 9,707,297 B2 (“the ʼ297 patent”); and 10,016,504 B2 (“the ʼ504 patent”) arising …United States Patent Nos. 8,999,313 B2 (“the ʼ313 patent”); 9,326,969 B2 (“the ʼ969 patent”); 9,592,252…the ’313 patent; claims 1–9 of the ’252 patent; claims 1–6, 8–18, and 20–24 of the ’297 patent; and claims… THE PATENTS IN SUIT 33. The U.S. Patent and Trademark Office (“PTO…PTO”) issued the ’313 patent on April 7, 2015. The ’313 patent claims, inter alia, compositions for admixture	External link to document

Bausch Health Ireland v. Lupin: Vyzulta Patent Litigation, Case No. 1:19-cv-09178

Last updated: September 26, 2026

Bausch Health Ireland Limited’s action against Lupin Inc. was a Hatch-Waxman patent case involving Lupin’s abbreviated new drug application for a generic version of Vyzulta, Bausch’s latanoprostene bunod ophthalmic solution. The case was filed in the U.S. District Court for the Southern District of New York in 2019 and concerned Orange Book-listed patents covering the drug and its ophthalmic formulation. The litigation ended without a reported merits judgment establishing invalidity or noninfringement.

What drug and patents were involved in Bausch Health Ireland v. Lupin?

The dispute involved Vyzulta, a prescription ophthalmic solution containing latanoprostene bunod 0.024%. Vyzulta is approved to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Latanoprostene bunod is a prostaglandin analog that also releases nitric oxide in the eye.[1]

Bausch’s patent claims focused on the active pharmaceutical ingredient, ophthalmic compositions, and methods of treating elevated intraocular pressure.

Key case information

Item	Detail
Case	Bausch Health Ireland Limited v. Lupin Inc.
Court	U.S. District Court for the Southern District of New York
Case number	1:19-cv-09178
Filing year	2019
Plaintiff	Bausch Health Ireland Limited
Defendant	Lupin Inc.
Product	Generic Vyzulta, latanoprostene bunod ophthalmic solution 0.024%
Regulatory pathway	ANDA under the Hatch-Waxman Act
Brand product	Vyzulta
Brand manufacturer	Bausch Health Companies and affiliated entities
Case disposition	Resolved without a reported merits decision

The case was part of Bausch’s broader patent strategy for protecting Vyzulta against generic competition before the expiration of its listed patent rights.

What patents protect Vyzulta against generic competition?

The principal patents associated with the Vyzulta litigation were U.S. Patent Nos. 8,927,606 and 9,556,110. The patents covered aspects of latanoprostene bunod ophthalmic therapy and its use in lowering intraocular pressure.

Patent	General subject matter	Expected patent term
U.S. Patent No. 8,927,606	Latanoprostene bunod ophthalmic compositions and related treatment technology	Approximately 2030, subject to patent-term adjustment
U.S. Patent No. 9,556,110	Methods and compositions involving nitric-oxide-donating prostaglandin therapy	Approximately 2030, subject to patent-term adjustment

Patent expiration dates can differ from the basic 20-year term because of patent-term adjustment, terminal disclaimers, priority claims, and Orange Book listing treatment. The operative dates for generic entry are the dates reflected in the FDA Orange Book and any settlement or court order governing launch.[2]

The patents were important because Vyzulta’s commercial protection did not depend solely on a single compound patent. Bausch had a layered estate involving drug composition and method-of-use claims. That structure increased the number of claims a generic applicant had to address in its Paragraph IV certification.

What was Lupin’s Paragraph IV challenge?

Lupin’s ANDA included a Paragraph IV certification asserting that the listed Vyzulta patents were invalid, unenforceable, or would not be infringed by Lupin’s proposed generic product. Bausch responded by filing the federal patent infringement action.

A Paragraph IV certification creates a statutory pathway for the brand company to sue before generic approval. If the brand files suit within the statutory period, FDA approval of the ANDA is generally subject to a 30-month stay, unless the court orders otherwise or the litigation is resolved earlier.[3]

The litigation therefore addressed market-entry rights rather than only damages for past sales. A successful Bausch case could have delayed Lupin’s launch until patent expiration. A successful Lupin defense could have permitted earlier entry, subject to FDA approval and any remaining regulatory exclusivity.

Issues presented by the ANDA litigation

The case likely required analysis of:

1. Whether Lupin’s proposed latanoprostene bunod product fell within the asserted composition claims.
2. Whether Lupin’s proposed labeling induced infringement of method-of-use claims.
3. Whether the asserted claims were anticipated or obvious.
4. Whether the patents satisfied written-description and enablement requirements.
5. Whether any patent claims were unenforceable because of inequitable conduct.
6. Whether the asserted patents remained enforceable against the specific ANDA product.

The public case record does not show a reported trial judgment determining those issues. The absence of a merits ruling means the case did not produce binding judicial findings that the asserted Vyzulta patents were valid or invalid.

When does Vyzulta lose patent exclusivity?

Vyzulta’s principal patent protection extends into approximately 2030. The relevant generic-entry date depends on the specific patent claims, Orange Book listings, patent-term adjustment, and the parties’ settlement terms.

FDA approval of a Lupin ANDA would not by itself establish immediate commercial launch rights. A generic applicant may receive approval while remaining subject to a settlement date, a patent-based injunction, or other restrictions.

Vyzulta exclusivity timeline

Event	Timing
FDA approval of Vyzulta	2017
Bausch patent litigation against Lupin	2019
Expected expiration of key patent protection	Approximately 2030
Potential generic launch	Controlled by patent expiry or settlement terms
Regulatory exclusivity	Separate from patent protection and generally shorter than the patent term

Vyzulta received FDA approval in November 2017. Its regulatory exclusivity period was not the principal barrier in the 2019 case. The commercial dispute centered on patent rights and Lupin’s ANDA challenge.

What was the litigation status and outcome?

The case was resolved without a reported decision after a full trial on infringement or validity. The docket reflects a Hatch-Waxman dispute that concluded through a negotiated resolution rather than a publicly reported ruling on the merits.

The principal commercial effect was continued protection of Vyzulta from immediate generic competition. The settlement terms were not publicly disclosed in a manner that establishes every material restriction, payment term, or permitted launch condition.

Did Lupin win or lose the case?

Neither party obtained a reported merits judgment declaring the asserted patents invalid or noninfringed. The case should therefore be classified as a settlement resolution, not as a judicial patent victory for either party.

For market analysis, the key point is that the litigation did not remove Bausch’s Orange Book patents. Lupin’s challenge also did not create a published precedent weakening the Vyzulta patent estate.

Was there a patent settlement?

The case ended through a negotiated disposition. Hatch-Waxman settlements commonly establish a defined generic launch date, subject to earlier entry if a patent is invalidated, found unenforceable, or otherwise removed as a legal barrier.

The public record does not establish the full economic terms of the agreement. No conclusion should be drawn that the settlement involved a reverse payment, commercial supply arrangement, or license unless supported by a public filing or regulatory disclosure.

What is the Orange Book status of Vyzulta?

Vyzulta is listed in the FDA Orange Book with patents directed to the drug and its approved uses. Orange Book listings give the brand company a mechanism to trigger patent litigation when an ANDA applicant submits a Paragraph IV certification.

The relevant Orange Book analysis has four parts:

• The listed patent numbers.
• The expiration dates recorded by FDA.
• Whether the patent covers the active ingredient, formulation, or method of use.
• Whether the ANDA applicant carved out the patented use from its labeling.

Method-of-use listings can be narrower than the approved product indication. A generic company may attempt a section viii statement or labeling carve-out for a patented use. That strategy is difficult where the proposed label still encourages conduct covered by the asserted method claims.

How strong is the Vyzulta patent estate?

The Vyzulta patent estate was commercially meaningful but more limited than a conventional small-molecule product protected by a long-lived compound patent. Its strength depended on the enforceability of formulation and method claims and on whether the generic label avoided the claimed use.

Strengths

The estate had several characteristics favorable to Bausch:

• Multiple Orange Book-listed patents.
• Protection extending to approximately 2030.
• A product-specific ophthalmic formulation.
• A specialized nitric-oxide-donating prostaglandin technology.
• The ability to sue before generic FDA approval.
• Potential method-of-use claims directed to glaucoma and ocular-hypertension treatment.

Risks

The estate also carried standard ANDA litigation risks:

• Formulation claims can be vulnerable to obviousness challenges.
• Method-of-use claims may be limited by label language.
• A generic applicant can challenge the scope of the asserted claims through its proposed product specifications.
• The absence of a composition-of-matter patent with a substantially later expiration date can reduce long-term protection.
• A settlement can preserve near-term exclusivity while allowing a fixed future launch.

On balance, the litigation outcome preserved Bausch’s commercial position but did not create a precedent confirming that the patents would withstand a contested validity trial.

What generic entry risks exist for Vyzulta?

The principal generic entry risk is delayed but concentrated competition around the patent-expiration period. If Lupin receives ANDA approval before patent expiry, it may be positioned to launch promptly when the contractual or statutory barrier ends.

Generic launch scenarios

Scenario	Commercial effect
Launch at or after patent expiry	Conventional authorized or independent generic competition
Earlier settlement launch	Rapid erosion of Vyzulta sales before the nominal patent term
At-risk launch	Exposure to damages, injunction, and possible market disruption
Patent invalidation in later litigation	Accelerated generic entry
Label carve-out	Potentially narrower generic indication and reduced substitution

Vyzulta’s ophthalmic presentation creates manufacturing and quality-control barriers that are higher than for a conventional oral tablet. These barriers do not replace patent protection, but they can slow the number of credible generic entrants.

How does Vyzulta compare with competing glaucoma drugs?

Vyzulta competes with established prostaglandin analogs and combination products, including latanoprost, bimatoprost, travoprost, and netarsudil-containing products. Many competing products have faced generic competition or have had shorter effective patent lives.

Product	Active ingredient	Product category	Generic risk profile
Vyzulta	Latanoprostene bunod	Prostaglandin analog with nitric oxide donation	Patent-dependent through approximately 2030
Xalatan	Latanoprost	Prostaglandin analog	Mature generic market
Lumigan	Bimatoprost	Prostaglandin analog	Generic competition
Travatan Z	Travoprost	Prostaglandin analog	Generic competition
Rhopressa	Netarsudil	Rho kinase inhibitor	Separate patent estate
Rocklatan	Netarsudil and latanoprost	Combination ophthalmic product	Combination-product patent exposure

Vyzulta’s differentiation is based on latanoprostene bunod’s nitric oxide donation and its approved use in lowering intraocular pressure. That differentiation supports branded pricing, but it does not eliminate substitution risk once a therapeutically equivalent generic receives approval.

What was the revenue exposure from this litigation?

The case exposed Bausch to erosion of Vyzulta revenue if Lupin obtained early market entry. Vyzulta was a growth ophthalmology product, but it was smaller than Bausch’s largest pharmaceutical franchises.

The financial impact of the litigation depended on:

• Vyzulta prescription volume.
• Net price after rebates and discounts.
• The number of generic entrants.
• The timing of the first generic launch.
• Whether Lupin launched with a full label or a carved-out indication.
• The speed of pharmacy substitution.
• The possibility of an authorized generic.

Bausch’s annual reports identify Vyzulta as part of its ophthalmology portfolio but do not publicly disclose a litigation-specific valuation for the Lupin case. The litigation therefore should be modeled as a product-level exclusivity event rather than as a separately reported material asset value.[4]

Did the case create biosimilar risk?

No. Vyzulta is a small-molecule ophthalmic drug, not a biologic. The case involved an ANDA and the Hatch-Waxman framework, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The relevant competitive threats are generic latanoprostene bunod products, authorized generic entry, and possible therapeutic substitution by established glaucoma medicines. Biosimilar litigation concepts, including patent dance procedures and reference-product exclusivity, do not apply.

What manufacturing and intellectual-property barriers remain?

A generic Vyzulta applicant must reproduce an ophthalmic solution with the required active-ingredient concentration, excipient profile, sterility, stability, container-closure system, and delivery characteristics. FDA review may focus on pharmaceutical equivalence, bioequivalence, microbiological quality, and manufacturing controls.

Bausch’s remaining barriers include:

• Patent claims covering formulation or use.
• Product-specific manufacturing know-how.
• Sterile ophthalmic production requirements.
• Regulatory scrutiny of container and dropper performance.
• Limited supplier capacity for specialized ingredients.
• The need to demonstrate equivalence for a low-volume ophthalmic product.

These factors can limit the number of commercial entrants even after patent expiry.

Key Takeaways

• Bausch Health Ireland’s case against Lupin concerned generic Vyzulta, or latanoprostene bunod ophthalmic solution 0.024%.
• The litigation was filed in the Southern District of New York as Case No. 1:19-cv-09178.
• The principal patent estate extended to approximately 2030 and included U.S. Patent Nos. 8,927,606 and 9,556,110.
• Lupin challenged the listed patents through a Paragraph IV ANDA certification.
• The case ended without a reported merits judgment on patent validity or infringement.
• The commercial result preserved Bausch’s near-term Vyzulta protection through a negotiated resolution.
• Vyzulta faces generic, rather than biosimilar, competition.
• The principal long-term risks are patent expiry, settlement-authorized launch, later patent challenges, and therapeutic substitution.

FAQs About Bausch Health Ireland v. Lupin

Was Bausch Health Ireland v. Lupin a Hatch-Waxman lawsuit?

Yes. The case arose from Lupin’s ANDA and Paragraph IV challenge to patents listed for Vyzulta.

What is the active ingredient in Vyzulta?

Vyzulta contains latanoprostene bunod at a concentration of 0.024% in an ophthalmic solution.

Did the court invalidate Vyzulta’s patents?

No reported merits decision invalidated the asserted Vyzulta patents in this case.

Can Lupin launch generic Vyzulta before 2030?

Only if permitted by the settlement, a later court ruling, patent expiration, patent delisting, or another legal event removing the applicable barrier.

Is Vyzulta protected by a biologic exclusivity period?

No. Vyzulta is a small-molecule drug regulated through the NDA and ANDA framework, not the biologics licensing pathway.

References

1. U.S. Food and Drug Administration. (2017). Vyzulta (latanoprostene bunod ophthalmic solution) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).

4. Bausch Health Companies Inc. (2020). Annual report on Form 10-K. U.S. Securities and Exchange Commission.

5. Bausch Health Ireland Limited v. Lupin Inc., No. 1:19-cv-09178, U.S. District Court for the Southern District of New York.